Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
EXACT SCIENCES CORPORATION |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 64.78 USD | -0.27% | -3.39% | +30.80% | |
Financials (USD)
| Sales 2023 * | 2.48B | Sales 2024 * | 2.83B | Capitalization | 11.75B |
|---|---|---|---|---|---|
| Net income 2023 * | -261M | Net income 2024 * | -201M | EV / Sales 2023 * | 5,43x |
| Net Debt 2023 * | 1.71B | Net Debt 2024 * | 1.52B | EV / Sales 2024 * | 4,69x |
| P/E ratio 2023 * | -45,2x | P/E ratio 2024 * | -60,0x | Employees | 6,350 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.06% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.31% | ||
| 1 week | +1.50% | ||
| Current month | +1.50% | ||
| 1 month | -0.52% | ||
| 3 months | -17.66% | ||
| 6 months | -25.98% | ||
| Current year | +31.21% |
1 week
63.24
67.27
1 month
58.4369.26
Current year
45.89100.77
1 year
43.90100.77
3 years
29.27159.54
5 years
29.27159.54
10 years
4.67159.54
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Conroy
CEO | Chief Executive Officer | 57 | 2009 |
Jeffrey Elliott
DFI | Director of Finance/CFO | 45 | 2016 |
Paul Limburg
CTO | Chief Tech/Sci/R&D Officer | - | 2018 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
D. Coward
BRD | Director/Board Member | 58 | 2014 |
Kevin Conroy
CEO | Chief Executive Officer | 57 | 2009 |
Freda Lewis-Hall
BRD | Director/Board Member | 67 | 2020 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.46% | 1,356 M€ | 0.00% | - | |
| 9.71% | 2 M€ | +0.57% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 64.74 | -0.34% | 729 862 |
| 23-12-07 | 64.96 | -0.31% | 933,939 |
| 23-12-06 | 65.16 | +0.60% | 1,187,679 |
| 23-12-05 | 64.77 | -1.36% | 1,228,348 |
| 23-12-04 | 65.66 | -2.04% | 1,350,927 |
Delayed Quote Nasdaq, December 07, 2023 at 03:59 pm EST
More quotes
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company's products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue.
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
64.96USD
Average target price
90.02USD
Spread / Average Target
+38.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.21% | 11 748 M $ | |
| -0.97% | 2 937 M $ | |
| +5.44% | 1 827 M $ | |
| +5.32% | 1 722 M $ | |
| -6.80% | 898 M $ | |
| -63.80% | 685 M $ | |
| -39.01% | 675 M $ | |
| -14.72% | 526 M $ | |
| 0.00% | 288 M $ | |
| -11.60% | 205 M $ |
